Ilmodol antinfiamamtorio and antirheumatic 24 tablets

Pregnancy and breastfeeding

Naproxen is contraindicated in the last trimester of pregnancy due to the risk of cardiopulmonary and renal toxicity to the fetus. It should not be used in the first and second months unless considered essential by the treating physician. Delayed parturition has been observed in animals (it is not known whether this effect also occurs in humans).

Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%.

The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. Additionally, an increased incidence of various malformations, including cardiovascular, has been reported in animals with anemia and stupor. Rare: depression, malaise, aseptic meningitis, cognitive disorders. Musculoskeletal and connective tissue effects. Myalgia, muscle weakness. Hematological effects. Rarely: agranulocytosis, eosinophilia, leukopenia, thrombocytopenia, granulocytopenia, aplastic anemia, and hemolytic anemia. Cardiovascular effects. Common: palpitations; Rare: congestive heart failure, vasculitis, tachycardia. Respiratory effects. Rare: pneumonia, eosinophilia, bronchospasm, alveolitis, laryngeal edema, asthma. Endocrine and metabolic effects. Rare: hyperglycemia, hypoglycemia. Others: visual disturbances, hearing impairment, peripheral edema. Anaphylactic reactions to naproxen and naproxen sodium preparations have been reported in patients with or without a history of hypersensitivity to nonsteroidal anti-inflammatory drugs.

If you experience any other undesirable effects not described and resulting from the use of the drug, inform your doctor or pharmacist. who were administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimesters of pregnancy, the drug should not be administered unless strictly necessary. If used by a woman attempting to conceive, or during the first and second trimesters of pregnancy, the dose and duration of treatment should be kept as low as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the newborn, at the end of pregnancy, to: possible prolongation of bleeding time, and antiplatelet effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, it is contraindicated during the third trimester of pregnancy. Naproxen has been found in breast milk, therefore the use of naproxen should be avoided in breastfeeding patients.

Format

24 tablets